Clinical trialNCT06744920RecruitingPhase 3Interventional

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

SponsorNovartis PharmaceuticalsEnrollment180Generalized Myasthenia Gravis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

130 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Recruiting
Novartis Investigative Site
Caba, Argentina
Recruiting
Novartis Investigative Site
Capital Federal, Argentina
Recruiting
Novartis Investigative Site
San Miguel de Tucumán, Argentina
Recruiting

Australia

Novartis Investigative Site
Kogarah, New South Wales, Australia
Recruiting
Novartis Investigative Site
Fitzroy, Victoria, Australia
Recruiting
Novartis Investigative Site
Southport, Australia
Recruiting

Belgium

Novartis Investigative Site
Leuven, Vlaams Brabant, Belgium
Recruiting

Brazil

Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Recruiting
Novartis Investigative Site
Brasília, Federal District, Brazil
Recruiting
Novartis Investigative Site
Caxias do Sul, Rio Grande do Sul, Brazil
Recruiting
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Recruiting
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Recruiting

Canada

Novartis Investigative Site
Edmonton, Alberta, Canada
Recruiting
Novartis Investigative Site
London, Ontario, Canada
Recruiting
Novartis Investigative Site
Ottawa, Ontario, Canada
Recruiting
Novartis Investigative Site
Québec, Quebec, Canada
Recruiting

China

Novartis Investigative Site
Hefei, Anhui, China
Recruiting
Novartis Investigative Site
Guangzhou, Guangdong, China
Recruiting
Novartis Investigative Site
Shijiazhuang, Hebei, China
Recruiting
Novartis Investigative Site
Zhengzhou, Henan, China
Recruiting
Novartis Investigative Site
Wuhan, Hubei, China
Recruiting
Novartis Investigative Site
Wuxi, Jiangsu, China
Recruiting
Novartis Investigative Site
Changchun, Jilin, China
Recruiting
Novartis Investigative Site
Beijing, China
Recruiting
Novartis Investigative Site
Beijing, China
Recruiting
Novartis Investigative Site
Qingdao, China
Recruiting
Novartis Investigative Site
Shanghai, China
Recruiting
Novartis Investigative Site
Shanghai, China
Recruiting

France

Novartis Investigative Site
Bordeaux, France
Recruiting
Novartis Investigative Site
Nice, France
Recruiting
Novartis Investigative Site
Paris, France
Recruiting
Novartis Investigative Site
Paris, France
Recruiting
Novartis Investigative Site
Strasbourg, France
Recruiting
Novartis Investigative Site
Toulouse, France
Recruiting

Georgia

Novartis Investigative Site
Kutaisi, Georgia
Recruiting
Novartis Investigative Site
Tbilisi, Georgia
Recruiting
Novartis Investigative Site
Tbilisi, Georgia
Recruiting

Germany

Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Recruiting

90 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Remibrutinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Feb 2025
Primary completion: 25 Feb 2028
Completion: 26 Feb 2033
Last update posted: 29 Jul 2026
Registered enrollment: 180
Registry id: NCT06744920

Cross-registrations

EU-CTR / CTIS (EudraCT)2023-510026-32

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.